Skip to main
LENZ

LENZ Stock Forecast & Price Target

LENZ Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 60%
Buy 20%
Hold 20%
Sell 0%
Strong Sell 0%

Bulls say

LENZ Therapeutics is a late-stage biopharmaceutical company with a positive outlook due to its strong financial position with $220.0M in cash and its novel product VIZZ, which offers a safe and effective alternative for reading glasses patients with its minimized ciliary muscle involvement. Additionally, LENZ's global expansion plans and exclusive distribution agreements provide a strong foundation for future growth potential. Risks to the investment include potential failure to achieve peak revenue estimates and securing necessary capital resources.

Bears say

LENZ Therapeutics is facing challenges in obtaining significant revenue from its recently launched VIZZ product due to lower than expected rx volume and hampered by the 9% increase since the last quarter. Furthermore, the company is facing financial struggles as evident from the increased impairment costs in the 2Q26 earnings report, leading to a potential decrease in profitability and lower stock prices in the future. Despite some initial success with around 46K filled prescriptions and the initiation of DTC campaign, the company's expansion strategy through increased sales force deployment may not have a significant impact in the short term, leading to a negative outlook on the stock.

LENZ has been analyzed by 5 analysts, with a consensus rating of Buy. 60% of analysts recommend a Strong Buy, 20% recommend Buy, 20% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of LENZ Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About LENZ Therapeutics Inc (LENZ) Forecast

Analysts have given LENZ a Buy based on their latest research and market trends.

According to 5 analysts, LENZ has a Buy consensus rating as of Aug 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $28.80, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $28.80, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

LENZ Therapeutics Inc (LENZ)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.